US researchers identify protein called Tudor-SN that slows down cancer development

us-researchers-identify-protein-called-tudor-sn-that-slows-down-cancer-development
identify protein called Tudor-SN

Nothing is impossible in science. But cancer is an extremely complex disease which leads people to death and earlier it was an incurable but the researchers, scientists etc of all over the world have found many effective ways, medicines to cure this very dangerous disease. Researchers again found an effective way to slow the fast-growing cells that characterize all types of cancer.

Researchers identified a protein called Tudor-SN that is important in the “preparatory” phase of the cell cycle the period when the cell gets ready to divide. When scientists eliminated this protein from cells, using the gene editing technology CRISPR-Cas9, cells took longer to gear up for division. The loss of Tudor-SN slowed the cell cycle.

“We know that Tudor-SN is more abundant in cancer cells than healthy cells, and our study suggests that targeting this protein could inhibit fast-growing cancer cells,” said Reyad A. Elbarbary, Ph.D., lead study author and research assistant professor in the Center for RNA Biology and the department of Biochemistry and Biophysics at the University of Rochester School of Medicine and Dentistry.

Elbarbary, who works in the laboratory of senior study author Lynne E. Maquat, Ph.D., a world-renowned expert in RNA biology, adds that there are existing compounds that block Tudor-SN that could be good candidates for a possible therapy.

“Because cancer cells have a faulty cell cycle, pursuing factors involved in the cell cycle is a promising avenue for cancer treatment,” noted Maquat, director of the Center for RNA Biology and the J. Lowell Orbison Endowed Chair and professor of Biochemistry and Biophysics.

Maquat, who also holds an appointment in the Wilmot Cancer Institute, and Elbarbary have filed a patent application for methods targeting Tudor-SN for the treatment and prevention of cancer. Research next steps include understanding how Tudor-SN works in concert with other molecules and proteins so that scientists can identify the most appropriate drugs to target it.

Read Previous

Zydus Wellness consolidated income from operations up by 14.4% in Q4

Read Next

Growing health consciousness expected to keep demand strong says research

Leave a Reply